Back to results
US 2022/0154147 A1Published application
Immunomodulating mesenchymal stem cells
OwnerJan SPAAS, Sarah BROECKXinventors
Life of this patent
Estimating the term…
Abstract
The current invention concerns an isolated mesenchymal stem cell wherein said cell is measuredpositive for mesenchymal markers CD29, CD44 and CD90; and negative for MHC class II molecules,whereinsaid cell secretes immunomodulatory prostaglandin E2 cytokine when present in an inflammatory environment or condition. The current invention also concerns a cell composition comprising said cells and the use thereof in the treatment of immune-related diseases and inflammatory conditions.
Claims14
An isolated mesenchymal stem cell wherein said cell is measured
- a. positive for mesenchymal markers CD29, CD44 and CD90;
- and
- b. negative for MEW class II molecules,
- characterized in that said cell secretes immunomodulatory prostaglandin E2 cytokine when present in an inflammatory environment or condition.
1 more element
Dependencies are inferred from the claim text.